经济观察网拓新药业（301089）近7天股价呈现震荡下行态势，累计跌幅0.38%。技术指标显示股价处 于弱势区间。公司股东人数近期增长6.46%，筹码集中度出现波动。公司此前发布的2025年业绩预告显 示全年预亏。 股票近期走势 近7天，拓新药业股价呈现震荡下行态势，从02月04日收盘价29.32元下跌至02月11日最新价29.21元，累 计跌幅0.38%。02月11日单日跌幅0.31%，振幅0.61%，换手率1.12%，成交金额2990万元，主力资金净 流出14.58万元。技术面上，当前股价处于布林带下轨附近，20日移动平均线为30.089元，短期压力位 32.82元，支撑位27.51元。MACD指标显示差离值为-0.235，处于弱势区间。 近期事件 股权变动方面，2026年02月04日公司披露股东人数较2026年01月20日增长1134户，增幅6.46%，总户数 达1.75万户，户均持股数量变化显示筹码集中度波动。公司经营层面，近7天无新增重大公告。2026年 01月26日发布的2025年业绩预告仍受市场关注，公司预计全年亏损5400万元至7300万元，亏损同比扩 大。 以上内容基于公开资料整理，不构成投 ...

2月10日，多家上市公司通过互动平台、披露投资者关系活动记录表等渠道披露公司在火箭发射、光伏 等方面最新情况： 【火箭发射】 华宝新能：公司户外电源产品在国内火箭发射等多个高难度离网电力场景中已广泛应用 泰胜风能：公司火箭贮箱项目预计将于2026年年中正式投产 【电池】 【脑机接口】 拓新药业：公司目前产品及业务暂不涉及脑机接口相关领域 【传媒】 【其他】 (本文来自第一财经) 泰和科技：公司原磷酸铁锂生产装置改造完成后预计可形成年产1万吨磷酸焦磷酸铁钠生产规模 【光伏】 泽润新能：公司目前暂未就太阳翼接线盒进行研发 博纳影业：公司参与出品《飞驰人生3》 该影片已定档2026年春节档全国院线上映 宋城演艺：公司目前暂未与美国特斯拉公司建立业务合作关系 立昂技术：将持续加大对算力、云计算、云服务行业的研发投入 信维通信：目前公司直接持有信维电科15%股份 博思软件：目前林芝腾讯仍持有公司股份 信科移动：公司卫星互联网业务尚处于投入期 北京君正：公司新制程的产品将从一季度陆续开始进入大规模销售阶段 新宝股份：咖啡机自主品牌Barsetto国内销售额占比还很小 ...

格隆汇2月10日丨拓新药业(301089.SZ)在投资者互动平台表示，公司目前产品及业务暂不涉及脑机接口 相关领域。未来，公司将继续聚焦核心主业，同时积极开拓大健康功能食品原料药市场。 ...

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

【导读】印度尼帕病毒疫情引关注，相关概念股大涨，多家公司紧急回应 据央视新闻报道，尼帕病毒病主要通过直接接触感染的动物、病人及污染物传播，病毒环境存活力弱，一般民众接触感染机会较少。本 次印度暴发的尼帕病毒病疫情，主要发生在西孟加拉邦，该地区与我国没有领土接壤。 综合研判，此次印度尼帕病毒病疫情对我国产生的影响相对较小。目前，我国尚未发现尼帕病毒病病例。但也存在一定境外输入风险， 需加强防范。 据悉，尼帕病毒感染潜伏期为3至14天，初期症状与流感相似，易出现误诊。这也意味着，早期精准检测不仅能为临床干预争取时间， 也是落实国境检疫、疫情溯源的核心环节。 随着尼帕病毒疫情持续发酵，市场对病毒防治、体外诊断等相关概念股的关注明显升温。截至1月27日收盘，相关板块个股集体走强， 凯普生物（300639）、达安基因（002030）斩获两连板；拓新药业（301089）、利德曼（300289）、特一药业（002728）等个股涨幅居 前。 | 凯普生物 | 8.70 | 20.00% | 1.45 | | --- | --- | --- | --- | | 300639 倍 | | | | | ■正制 2天2板 入气龙头一 ...

Core Viewpoint - The company,拓新药业, is forecasting a significant increase in losses for the fiscal year 2025, projecting a loss between 54 million to 73 million yuan, which is a substantial increase compared to the previous year's loss of approximately 19.88 million yuan [1]. Financial Performance - For the first three quarters of 2025, the company's operating revenue decreased by 16.64%, with a net loss of approximately 30.16 million yuan, indicating that the fourth quarter of the previous year alone saw losses exceeding the total losses of the first three quarters [1]. - The company has reported consecutive annual losses for two years, with the loss margin increasing significantly [1]. Management Response - In response to the ongoing losses, the company is actively implementing multiple measures aimed at improving operational performance and achieving profitability [1][2]. - The company acknowledges that the decline in overall business performance is primarily due to fluctuations in demand and declining market prices for certain raw material products, which have adversely affected sales revenue and gross margins [2]. - The company is also facing high fixed costs due to the gradual release of new production capacity from completed investment projects, which is putting pressure on current profits [2]. Shareholder Actions - The company's major shareholder, 伊沃斯, has reduced its stake in the company, decreasing its ownership from 29.84% to 27.37% after a series of share reductions totaling 3.12 million shares [3]. - Despite an influx of financing in 2026, the company's financing balance has decreased, falling to 136 million yuan from 144 million yuan, a decline of over 6% [3].

Group 1 - The company expects a loss of 54 million to 73 million yuan in 2025, with a non-recurring loss of 62 million to 84 million yuan [1] - The market environment has negatively impacted the company's sales revenue and gross margin due to fluctuations in terminal demand and declining market prices for certain raw material products [1] - The company's operational development is affected by high fixed costs during the gradual release of new production capacity from completed fundraising projects, as well as high unit costs from small-scale production of new health products set to launch in 2025 [1]

证券日报网讯1月23日，拓新药业（301089）发布2025年度业绩预告称，公司预计2025年度归属于上市 公司股东的净利润亏损5，400万元–7，300万元，上年同期亏损1，988.49万元，比上年同期下降 171.56%-267.11%。 ...

（文章来源：证券日报） 证券日报网讯 1月23日，拓新药业在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东 户数17542户。 ...

拓新药业（301089）(301089.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损5400 万元–7300万元;扣除非经常性损益后的净亏损6200万元–8400万元。 ...